AI / ML INNOVATIONS INC - AIMLF STOCK NEWS

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) has provided a status update regarding its management cease trade order (MCTO) granted by the British Columbia Securities Commission on August 29, 2024. The MCTO restricts trading for the CEO and Interim CFO until the company files its annual financial documents for the year ended April 30, 2024. The company now expects to file these documents by September 30, 2024, citing ongoing work with auditors on accounting issues related to a French investee entity.

AI/ML Innovations is focused on artificial intelligence and machine learning in digital health and wellbeing. The company has investments in Health Gauge (70% owned), Tech2Heal (22% ownership commitment), and AI Rx Inc. (70% owned), aiming to capitalize on growth areas in healthcare management solutions and precision support delivery.

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) has been granted a Management Cease Trade Order (MCTO) by the British Columbia Securities Commission due to a delay in filing its audited annual financial statements for the year ended April 30, 2024. The MCTO restricts trading in company securities by the CEO and CFO but does not generally affect other shareholders' ability to trade. The company expects to file the required documents by September 15, 2024.

AI/ML Innovations focuses on artificial intelligence and machine learning technologies in digital health and wellbeing. The company has investments in Health Gauge (70% owned), Tech2Heal (22% ownership commitment), and AI Rx Inc. (70% owned).

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) has announced a delay in filing its annual financial disclosure for the year ended April 30, 2024. The company has applied for a management cease trade order (MCTO) from the British Columbia Securities Commission to avoid a general cease trade order. The delay is due to the inability of bookkeepers from its investee, Tech2Heal, to provide necessary financial information for audit completion.

The company expects to file the required documents by September 15, 2024, missing the original August 28, 2024 deadline. During the MCTO period, if granted, only insiders will be restricted from trading the company's securities. AI/ML Innovations focuses on artificial intelligence and machine learning in digital health and wellbeing, with investments in Health Gauge, Tech2Heal, and AI Rx Inc.

AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) has completed its acquisition of technology from Naiad Lab Inc. The company issued 6,700,000 shares at $0.05 per share to Naiad Lab, subject to a 12-month voluntary hold period. This acquisition aligns with AIML's focus on AI and machine learning technologies in digital health and wellbeing. AIML's strategy involves partnerships and investments in companies like Health Gauge Inc. (95.2% owned), Tech2Heal (up to 22% ownership rights), AI Rx Inc. (70% owned), and NeuralCloud Solutions Inc. (100% owned). The company aims to capitalize on expanding growth areas in AI-driven healthcare management solutions and precision support delivery.

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) has completed a non-brokered private placement, raising $392,250 through the issuance of 7,845,000 units at $0.05 per unit. Each unit comprises one common share and one warrant, exercisable at $0.10 for two years. The company paid $18,200 in finder's fees and issued 364,000 broker warrants. An insider subscribed for 23.96% of the units. The net proceeds will be used for working capital. Securities are subject to a hold period until December 20, 2024. AI/ML focuses on AI and machine learning investments in digital health and wellbeing companies.

AI/ML Innovations Inc. has entered into a Debt Settlement and Security Agreement with ThreeD Capital Inc. for a debt of $47,460 related to services provided. The debt will be settled through the issuance of 949,200 common shares at a price of $0.05 per share. This transaction is subject to approval by the Canadian Securities Exchange (CSE) and the shares will be restricted for a four-month period.

AI/ML Innovations focuses on investments in artificial intelligence (AI) and machine learning (ML) within the digital health sector. Their strategic partnerships include a 95.2% stake in Health Gauge, 12.44% ownership in Tech2Heal (right to increase up to 22%), and a 70% stake in AI Rx Inc.

The company's shares trade on the Canadian Securities Exchange under the symbol AIML, on the OTCQB under AIMLF, and on the Frankfurt Stock Exchange under 42FB.

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) has announced a proposed non-brokered private placement of up to 6,000,000 units at $0.05 per unit, aiming to raise up to $300,000. Each unit consists of one common share and one warrant, exercisable at $0.10 per share for two years. The company plans to use the net proceeds for working capital requirements. The private placement is subject to regulatory approvals, including from the Canadian Securities Exchange. AI/ML Innovations focuses on artificial intelligence and machine learning in the digital health and wellbeing sector, with investments in Health Gauge, Tech2Heal, and AI Rx Inc.

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) has completed its non-brokered private placement on July 17, 2024. The company raised a total of $971,500 by issuing 19,430,000 units at $0.05 per unit. Each unit consists of one common share and one warrant, exercisable at $0.10 for three years. The final tranche raised $511,500 from 10,230,000 units. AI/ML paid $26,477.60 in finder's fees and issued 529,550 broker warrants. The securities are subject to a hold period until November 18, 2024. The company plans to use the net proceeds for working capital requirements.

AI/ML Innovations, a leader in AI and machine learning solutions, announces a live webinar event on July 11th at 9:00 AM PT / 12:00 PM ET. Paul Duffy, CEO, will recap the past 90 days, discuss upcoming 90 days, and outline key Q3 milestones. The company focuses on AI and ML investments in digital health and well-being, with significant stakes in Health Gauge, Tech2Heal, and AI Rx Inc. Shares are traded under CSE: AIML, OTCQB: AIMLF, and FWB: 42FB.